Lees-Rolfe Garth bought IKT
January 3, 2025 · Form 4 insider transaction
Lees-Rolfe Garth bought 432,853 shares of Inhibikase Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
432,853
Price
$0.00
Total value
N/A
InsiderLees-Rolfe Garth
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJanuary 3, 2025
Filing dateJanuary 7, 2025
Shares owned after432,853
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The options will vest and become exercisable upon the expiration of the exercise period of the Issuer's Series B-1 Warrants in an amount proportional to the actual number of Series B-1 Warrants exercised, subject to the Reporting Person's continuous service to the Issuer through such date. Any options that do not become vested shall be automatically forfeited without consideration in respect thereof.